Navigation Links
Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
Date:2/19/2008

ASHBURN, Va., Feb. 19 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the second of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections, has commenced dosing.

GENTAMICIN SURGICAL IMPLANT is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) directly to the target tissue for localized action, while maintaining low systemic levels well below the toxicity threshold. The product was developed using Innocoll's proprietary collagen-based drug delivery technology, CollaRx, and (outside of the US) is indicated as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues. GENTAMICIN SURGICAL IMPLANT is already approved in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and there are more than 60 prospective clinical trials and published case reports totaling over 7,500 patients documenting its safety and efficacy over a broad range of orthopedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures.

According to advice from FDA received at both pre-IND and post-IND meetings held in 2007, Innocoll will conduct two multi-centered phase 3 clinical trials in the US to support the planned New Drug Application (NDA). The first trial in cardiac surgery patients at higher risk of surgical site infection commenced in December 2007. The second trial, which has now enrolled its first patient, is in general surgery patients undergoing open colorectal surgery. Innocoll has appointed Duke University's Duke Clinical Research Instit
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
5. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
10. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
11. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
(Date:12/17/2014)... NEW YORK , Dec. 17, 2014 /PRNewswire-USNewswire/ ... resonance imaging (MRI), the MRI market is seeing ... cardiovascular and breast MRI scans account for the ... providing a higher resolution of images, which are creating ... resonance imaging (MRI) market is growing at a ...
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. (NYSE ... closing of its offering of $125 million aggregate principal ... "Notes").  The Notes were offered and sold only to ... Securities Act of 1933, as amended (the "Securities Act"). ... rate of 3.75% per year, payable semiannually in arrears ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... both ethical and practical grounds, direct programming is ... pluripotent stem,cells.", WASHINGTON, Nov. 20 Two ... Cell unveil a proven way to,generate patient-matched human ... use of human embryos or human or animal ...
... of circulating cancer cells in 40,billion blood cells, ... WARREN, N.J., Nov. 20 Veridex, LLC ... (FDA) has granted an,expanded clearance for the CellSearch(TM) ... monitoring of metastatic colorectal cancer. CellSearch is currently,approved ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 2FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 3FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 4
(Date:12/20/2014)... Dress company LunaDress has recently announced its 2015 ... offering big discounts on all of its special occasion dresses ... own a perfect wedding gown. If you have no idea ... to LunaDress. Many different wedding dress styles and our dress ... and enjoy the current special offer, up to 80% off," ...
(Date:12/20/2014)... December 20, 2014 Recently, VogueQueen.com, a ... VogueQueen Big Sale Online for 2015. Great ... All new and old consumers can get a discount, ... at the company’s website before January 30, 2015. , ... dresses and launched a prom dress promotion. Many customers ...
(Date:12/20/2014)... 20, 2014 Atore, Inc, (San Francisco, ... launched first birthday focused portal on December 17th, 2014. ... launched in both US and Japan. , MERRY BIRTHDAY ... http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE is part ... the world. , Features, Choose from thousands of stock ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
(Date:12/19/2014)... Today, Balfleet.com , a leading dress ... formal dress promotion. All the old and new customers ... , Balfleet.com is well-known for its high quality trendy ... cocktail dresses and more. Its formal dresses are quality ... they can create an elegant look when paired with ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2
... The Speaker of Lok Sabha, Shri Somnath Chatterji has said ... priority in policy making and implementation of programmes. // ... the country and the children at Vaatsalaya Mela here today, ... that still women and children went struggling for their rightful ...
... certain inhaled asthma medications and similar chemicals produced in ... worsen conditions like lupus, heart failures, asthma and other ... led by Raymond Penn, Ph.D., and Matthew Loza, Ph.D, ... out the research, found that beta-agonists, such as those ...
... engaging people cured of leprosy to fight the stigma of the ... of leprosy in the state has fallen to 1.56 percent in ... 'Lok Doots' (Messenger of People), as the cured are called, have ... ,For instance, the prevalence rate in Ranchi has gone up ...
... cardiac arrest is a common and deadly event. Twenty percent of ... a sudden cardiac arrest; //barely 5% of people who have one ... comes out of the blue, but a new study suggests that ... 2006 issue of the Harvard Heart Letter. ,Studying cardiac arrest ...
... The Massachusetts Biologic Laboratories (MBL) of the University of ... India today announce //the formation of an historic collaboration ... approach for preventing rabies in people. ,The institutions ... antibody (MAB) created by scientists at the MBL, in ...
... often multi-tasking and walking the tightrope to make a success ... they can chew! Though, such qualities //are the epitome of ... a pat on the back for such back-breaking endeavors. ... ill-health due to the build up of stress and over ...
Cached Medicine News:Health News:Women and Children Issues Should Get Priority in India 2Health News:The Immune System May Be Altered By Certain Chemicals 2Health News:International Collaboration Takes Aim at Rabies 2Health News:International Collaboration Takes Aim at Rabies 3
... Heartlab delivers the performance and ... information management systems. As the ... services set the benchmark. When ... high-speed performance and technological longevity, ...
The only catheter designed specially for visualization of peripheral vessels: carotids, renals, and illiacs...
... technology constructs images using second harmonic ... and noise than fundamental-frequency components., Pure ... transmit distortion-free, fundamental-frequency ultrasound beams. And ... a pure sinusoidal wave, both the ...
AngioSpeed V series, it is an Angiography system designed for vascular treatment in various radiological regions, cardiology, and neurology. SHIMADZU brings you a single system with all units fused t...
Medicine Products: